Intensive glucose regulation in hyperglycemic acute coronary syndrome: Results of the randomized BIOMarker study to identify the acute risk of a coronary syndrome-2 (BIOMArCS-2) glucose trial

JAMA Internal Medicine

Volumn 173, Issue 20, 2013, Pages 1896-1904

  De Mulder, Maarten ^a   Umans, Victor A ^a   Cornel, Jan H ^a   Van Der Zant, Friso M ^a   Stam, Frank ^a   Oemrawsingh, Rohit M ^b,c   Akkerhuis, K Martijn ^b   Boersma, Eric ^b  

^a Northwest Clinics   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE MB; GLUCOSE; INSULIN; TROPONIN T;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CORONARY RISK; DEATH; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE PERFUSION; HEART SCINTISCANNING; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TEACHING HOSPITAL;

ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CREATINE KINASE; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL PERFUSION IMAGING; MYOCARDIUM; PROSPECTIVE STUDIES; TROPONIN T;

EID: 84888382125     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.10074     Document Type: Article

References (34)

1. Kosiborod M, Inzucchi SE, Krumholz HM, et al. Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation. 2008;117(8):1018-1027.
2. de Mulder M, Cornel JH, van der Ploeg T, Boersma E, Umans VA. Elevated admission glucose is associated with increased long-term mortality in myocardial infarction patients, irrespective of the initially applied reperfusion strategy. Am Heart J. 2010;160(3):412-419.
3. Kosiborod M, Rathore SS, Inzucchi SE, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation. 2005;111(23):3078-3086.
4. Deedwania P, Kosiborod M, Barrett E, et al American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2008;117(12):1610- 1619.
5. Stranders I, Diamant M, van Gelder RE, et al. Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. Arch Intern Med. 2004;164(9):982-988.
6. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000;355(9206):773-778.
7. Kadri Z, Danchin N, Vaur L, et al USIC 2000 Investigators. Major impact of admission glycaemia on 30 day and one year mortality in non-diabetic patients admitted formyocardial infarction: results from the nationwide French USIC 2000 study. Heart. 2006;92(7):910-915.
8. Bolk J, van der Ploeg T, Cornel JH, Arnold AE, Sepers J, Umans VA. Impaired glucose metabolism predicts mortality after amyocardial infarction. Int J Cardiol. 2001;79(2-3):207-214.
9. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111(11):1448-1454.
10. Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Effect of hyperglycemia and insulin in acute coronary syndromes. Am J Cardiol. 2007;99(11A):12H-18H.
11. Iwakura K, Ito H, Ikushima M, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol. 2003;41(1):1-7.
12. Malmberg K, Rydén L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26(1):57-65.
13. Malmberg K, Rydén L, Wedel H, et al; DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26(7):650-661.
14. Díaz R, Goyal A, Mehta SR, et al. Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA. 2007;298(20):2399-2405.
15. van der Horst IC, Zijlstra F, van't Hof AW, et al Zwolle Infarct Study Group. Glucose-insulinpotassium infusion in patients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol. 2003;42(5):784-791.
16. Selker HP, Beshansky JR, Sheehan PR, et al. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA. 2012;307(18):1925-1933.
17. Cheung NW, Wong VW, McLean M. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care. 2006;29(4):765-770.
18. Gerstein HC, Bosch J, Dagenais GR, et al ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319-328.
19. de Mulder M, Umans VA, Stam F, Cornel JH, Oemrawsingh RM, Boersma E. Intensive management of hyperglycaemia in acute coronary syndromes: study design and rationale of the BIOMArCS 2 Glucose trial. Diabet Med. 2011;28(10):1168- 1175.
20. Bassand JP, Hamm CW, Ardissino D, et al Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28(13):1598-1660.
21. Van deWerf F, Bax J, Betriu A, et al ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29(23):2909-2945.
22. de Mulder M, Zwaan E, Wielinga Y, Stam F, Umans VA. How to implement a clinical pathway for intensive glucose regulation in acute coronary syndromes. Crit Pathw Cardiol. 2009;8(2):72-78.
23. Vollmer RT, Christenson RH, Reimer K, Ohman EM. Temporal creatine kinase curves in acute myocardial infarction: implications of a good empiric fit with the log-normal function. Am J Clin Pathol. 1993;100(3):293-298.
24. Licka M, Zimmermann R, Zehelein J, Dengler TJ, Katus HA, Kübler W. Troponin T concentrations 72 hours after myocardial infarction as a serological estimate of infarct size. Heart. 2002;87(6):520-524.
25. Giannitsis E, Steen H, Kurz K, et al. Cardiac magnetic resonance imaging study for quantification of infarct size comparing directly serial versus single time-point measurements of cardiac troponin T. J Am Coll Cardiol. 2008;51(3):307-314.
26. Younger JF, Plein S, Barth J, Ridgway JP, Ball SG, Greenwood JP. Troponin-I concentration 72 h after myocardial infarction correlates with infarct size and presence of microvascular obstruction. Heart. 2007;93(12):1547-1551.
27. Katus HA, Remppis A, Scheffold T, Diederich KW, Kuebler W. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am J Cardiol. 1991;67(16):1360-1367.
28. Boersma E, Umans V, Comel JH, de Mulder M. Statistical analysis plan: BIOMArCS2 Glucose. https://biomarcscrf.secure.is.nl/Documents/ Statistical%20Analysis%20plan%20BIOMArCS2glucose%20-%20FINAL-%209-7-12.pdf. Accessed August 21, 2012.
29. Giugliano RP, White JA, Bode C, et al EARLY ACS Investigators. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009;360(21):2176-2190.
30. Wallentin L, Becker RC, Budaj A, et al PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057.
31. Goyal A, Mahaffey KW, Garg J, et al. Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J. 2006;27(11):1289-1297.
32. Steen H, Giannitsis E, Futterer S, Merten C, Juenger C, Katus HA. Cardiac troponin T at 96 hours after acute myocardial infarction correlates with infarct size and cardiac function. J Am Coll Cardiol. 2006;48(11):2192-2194.
33. Svensson AM, McGuire DK, Abrahamsson P, Dellborg M. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J. 2005;26(13):1255-1261.
34. Finfer S, Chittock DR, Su SY, et al NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283-1297.